Form 4: ASMB Officer Jeanette Bjorkquist Reports RSU Grant, Tax Sales

ASSEMBLY BIOSCIENCES officer Jeanette M. Bjorkquist reported an RSU grant and subsequent sell-to-cover transactions for tax obligations.

Summary

• Jeanette M. Bjorkquist, Principal Financial Officer and Principal Accounting Officer of ASSEMBLY BIOSCIENCES, INC. (ASMB), reported transactions involving the company's common stock.
• On March 29, 2026, Bjorkquist was granted 6,500 restricted stock units (RSUs) at a price of $0.
• These RSUs represent 65% of her annual equity grant and vest in four equal installments on March 29, 2027, March 29, 2028, March 29, 2029, and March 29, 2030, assuming continuous service.
• The remaining 35% of the annual RSU grant is contingent upon stockholder approval of an amendment to the Issuer's Amended and Restated 2018 Stock Incentive Plan.
• On March 30, 2026, Bjorkquist sold 312 shares of common stock at a weighted average price of $26.6502 per share.
• Also on March 30, 2026, an additional 16 shares of common stock were sold at a weighted average price of $27.49 per share.
• These sales were mandated 'sell-to-cover' transactions to satisfy tax withholding obligations related to the vesting and settlement of restricted stock units, not discretionary sales.
• Following these transactions, Bjorkquist directly beneficially owns 11,089 shares of common stock.
• An administrative error in a prior Form 4 resulted in 300 fewer shares being reported in Column 5 than previously stated, which has been corrected in this filing.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive. While the RSU grant is a positive sign of ongoing executive compensation, the contingent nature of a portion of the grant and the administrative correction of a prior error slightly temper the overall sentiment.

Positives

• The reporting person received a grant of 6,500 restricted stock units (RSUs), indicating ongoing equity compensation and alignment with company performance.
• The RSU grant is part of an annual equity grant, demonstrating a structured compensation plan for key officers.

Negatives

• The sale of 328 shares (312 + 16) by an officer, even if for tax purposes, reduces their direct beneficial ownership.
• A portion (35%) of the annual RSU grant is contingent on stockholder approval of a plan amendment, introducing a potential delay or uncertainty for the full grant.

Risks

• The full annual equity grant for the reporting person is subject to stockholder approval of an amendment to the Issuer's Amended and Restated 2018 Stock Incentive Plan, which could impact future equity compensation if not approved.

Future Outlook

A portion of the reporting person's annual equity grant (35%) is contingent upon future stockholder approval of an amendment to the company's 2018 Stock Incentive Plan, which will determine the full scope of her equity compensation.

Industry Context

StockSavvy.ai notes that routine Form 4 filings, such as this one, are common in the biotechnology and pharmaceutical sectors, reflecting standard executive compensation practices involving equity grants and subsequent tax-related share sales. These transactions typically do not indicate a change in strategic direction but rather the execution of pre-established compensation plans.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) as a significant component of executive compensation is a common practice across the biotechnology industry, aligning executive incentives with long-term shareholder value.
• The 'sell-to-cover' mechanism for tax withholding is a standard administrative procedure for equity awards, widely adopted by public companies to manage tax liabilities upon RSU vesting, comparable to practices at companies like Gilead Sciences or Amgen.

Corporate Governance

Stakeholder Impact

• Shareholders: The RSU grant aligns executive incentives with shareholder interests. The potential plan amendment, if approved, could lead to minor dilution but is necessary for ongoing equity compensation programs.
• Employees: The filing reflects standard equity compensation practices, which are generally positive for employee retention and motivation, particularly for key officers.

Next Steps

• Stockholder approval of an amendment to the Issuer's Amended and Restated 2018 Stock Incentive Plan is required for the remaining 35% of the annual RSU grant to be issued.
• The granted RSUs will vest in four equal installments on March 29, 2027, 2028, 2029, and 2030, assuming continuous service.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation (RSU grant and tax-related sales). It does not contain information that would fundamentally alter the investment thesis for ASSEMBLY BIOSCIENCES. The transactions are expected and administrative in nature, thus a 'hold' recommendation is appropriate as there's no new material information to warrant a change in position based solely on this filing.

Keywords

ASSEMBLY BIOSCIENCES, ASMB, Form 4, SEC filing, insider transaction, restricted stock units, RSU grant, officer compensation, equity compensation, sell-to-cover, stock sales, corporate governance